35,011 Pfizer Inc. $PFE Shares Sold by Global Retirement Partners LLC

Global Retirement Partners LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 19.4% during the third quarter, HoldingsChannel.com reports. The firm owned 145,171 shares of the biopharmaceutical company’s stock after selling 35,011 shares during the period. Global Retirement Partners LLC’s holdings in Pfizer were worth $4,140,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. raised its stake in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. State Street Corp increased its position in Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the period. Bank of New York Mellon Corp grew its holdings in Pfizer by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 57,879,546 shares of the biopharmaceutical company’s stock worth $1,393,739,000 after purchasing an additional 3,999,646 shares during the last quarter. Bank of America Corp DE acquired a new position in Pfizer during the 2nd quarter valued at approximately $1,049,602,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Pfizer by 4.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 36,157,306 shares of the biopharmaceutical company’s stock valued at $870,668,000 after purchasing an additional 1,634,374 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.8%

Shares of NYSE PFE opened at $27.57 on Friday. The firm’s 50-day moving average price is $28.83 and its 200-day moving average price is $27.02. The stock has a market capitalization of $157.12 billion, a price-to-earnings ratio of 9.20, a P/E/G ratio of 1.84 and a beta of 0.31. Pfizer Inc. has a 12-month low of $23.62 and a 12-month high of $31.44. The company has a current ratio of 1.42, a quick ratio of 1.10 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the business posted $0.87 EPS. Pfizer’s revenue was down .4% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 3.04 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is 245.71%.

Analyst Ratings Changes

Several analysts recently weighed in on PFE shares. Guggenheim lifted their target price on shares of Pfizer from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Cantor Fitzgerald raised their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Citigroup increased their price objective on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. DZ Bank cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, November 6th. Finally, Royal Bank Of Canada upped their price objective on Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a research report on Wednesday, November 4th. Six equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $30.32.

Read Our Latest Stock Analysis on PFE

Latest Pfizer News

Here’s some of the latest news about PFE:

  • Positive Sentiment: Pfizer’s agreement with Starna Therapeutics gives it rights outside Greater China to develop three in vivo CAR-T programs for autoimmune diseases. The deal expands Pfizer’s pipeline and could open a new avenue for growth beyond its existing products. Reuters article
  • Positive Sentiment: Recent commentary says new launches and acquisitions are helping Pfizer build toward a return to growth from 2029, potentially helping offset expected patent expirations. Zacks article
  • Positive Sentiment: Pfizer is scheduled to pay its 352nd consecutive quarterly dividend on Dec. 7, a long-running payout that may appeal to income-focused investors, though it is not a new increase. Dividend article

Pfizer Profile

(Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.